[Effect of losartan on renal and cardiovascular complications of patients with type 2 diabetes and nephropathy].

Hans Henrik Parving; Barry M. Brenner; Mark E. Cooper; Dick de Zeeuw; William F. Keane; William E. Mitch; Giuseppe Remuzzi; Steven Snapinn; Zhonxin Zhang; Shahnaz Shahinfar

Related publications

Article2001

Effects of Losartan on Renal and Cardiovascular Outcomes in Patients with Type 2 Diabetes and Nephropathy

Barry M. Brenner, Mark E. Cooper, Dick de Zeeuw, William F. Keane, William E. Mitch, Hans‐Henrik Parving, Giuseppe Remuzzi, Steven Snapinn, Zhonxin Zhang, Shahnaz Shahinfar

Article2004

Losartan in diabetic nephropathy

Norberto Perico, Piero Ruggenenti, Giuseppe Remuzzi

Article2004

Continuum of Renoprotection with Losartan at All Stages of Type 2 Diabetic Nephropathy

Giuseppe Remuzzi, Piero Ruggenenti, Annalisa Perna, Borislav D. Dimitrov, Dick de Zeeuw, Darcy A. Hille, Shahnaz Shahinfar, George W. Carides, Barry M. Brenner

Article2008

ACE Gene Polymorphism and Losartan Treatment in Type 2 Diabetic Patients With Nephropathy

Hans‐Henrik Parving, Dick de Zeeuw, Mark E. Cooper, Giuseppe Remuzzi, Nancy Liu, Jared Lunceford, Shahnaz Shahinfar, Peggy H. Wong, Paulette A. Lyle, Peter Rossing, Barry M. Brenner

Article2000

The losartan renal protection study — rationale, study design and baseline characteristics of RENAAL (Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan)

Barry M. Brenner, Mark E. Cooper, Dick de Zeeuw, Jean‐Pierre Grünfeld, William F. Keane, Kiyoshi Kurokawa, Janet B. McGill, William E. Mitch, Hans Henrik Parving, Giuseppe Remuzzi, Arthur Barcelos Ribeiro, Mark Schluchter, Duane Snavely, Zhongxin Zhang, Roger L. Simpson, Denise Ramjit, Shahnaz Shahinfar, RENAAL Study Investigators